U.S. Direct-to-Consumer Genetic Testing Market size is slated to exceed USD 4.5 billion by 2032, as per a new research report announced by Global Market Insights Inc.
Growing public awareness about DTC genetic tests in developed as well as emerging economies is a key driver behind U.S. DTC genetic testing market growth. The rising awareness levels are being driven by dedicated marketing initiatives by leading industry players, who are increasingly working on making their kits available on e-commerce as well as online retail platforms. Players are also focusing their efforts on developing higher quality DTC genetic testing kits that are more accurate and efficient.
Meanwhile, increasing investments on genome sequencing to identify the risk of developing cancer or other rare genetic disorders is positively shaping the industry outlook as well. In December 2022, the UK government invested over £175 million (~USD 212 million) towards cutting-edge genomics research.
Increasing consumer awareness to drive ancestry & relationship test segment share
U.S. DTC genetic testing market from the ancestry & relationship testing segment is likely to hit USD 1.4 billion by 2032. Growing awareness around ethnicity tests is expected to drive the segment progress in the country as tests such as 23andme and ancestry become more popular. Government approvals for relationship and ancestry tests in the region are positively influencing the segment expansion as well. Many industry players are working on improving the efficiency and accuracy of these tests, further spurring the revenue stream.
Browse key industry insights spread across 60 pages with 51 market data tables & 15 figures & charts from the report, “U.S. Direct-to-Consumer Genetic Testing Market Size By Test (Carrier Testing, Predictive Testing, Ancestry & Relationship Testing, Nutrigenomics Testing, Skincare Testing), By Technology (Targeted Analysis, Single Nucleotide Polymorphism (SNP) Chips, Whole Genome Sequencing (WGS)), By Distribution Channel (Online Platforms, Over-the-Counter), Industry Analysis Report, Application Potential, Competitive Market Share & Forecast, 2023 – 2032” in detail along with the table of contents:
Rising cases of rare genetic diseases to spur WGS technology segment
Driven by the growing incidence of rare genetic diseases, the whole genome sequencing technology segment is likely to grow at a rapid pace through 2032. The deployment of this technology in DTC tests presents detailed yet precise information for detecting outbreaks quickly. It also summarizes most of the variation present in a person’s genome. It helps study the entire genome and is useful for characterizing bacteria and tracking outbreaks.
Cost-effectiveness to fuel over-the-counter distribution channel segment growth
U.S. DTC genetic testing market value from over-the-counter segment is anticipated to cross over USD 780 million by 2032. The growing popularity and rising variety of over the counter DTC genetic testing solutions to augment the segment outlook. The high convenience, fewer side-effects, and cost-effective nature of OTC products are further likely to fuel the industry revenues. Moreover, better availability of DTC test kits is also shaping the segment scenario.
Mergers and acquisitions to outline the competitive landscape for U.S. DTC genetic testing market
The list of U.S. direct-to-consumer genetic testing market contenders includes names such as MyHeritage, Ambry Genetics, The SkinDNA Company Pty Ltd, Blueprint Genetics Oy, and 23andMe, Inc., among others. Many of these firms are prioritizing mergers and acquisition strategies to expand their market presence.
Explore More on Related Topics: